Endonovo Therapeutics (ENDV) 10-K 6 Apr 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Apr. 06, 2018	Jun. 30, 2017
Document And Entity Information
Entity Registrant Name	ENDONOVO THERAPEUTICS, INC.
Entity Central Index Key	1,528,172
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 7,634,351
Entity Common Stock, Shares Outstanding		341,345,596
Trading Symbol	ENDV
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash	$ 90,173	$ 55,533
Prepaid expenses and other current assets	21,000	247,321
Total current assets	111,173	302,854
Property Plant and Equipment, net	1,064	15,825
Patents, net	4,500,000
Total assets	4,612,237	318,679
Current Liabilities
Accounts payable and accrued expenses	2,714,041	4,727,247
Short term advances	20,323	5,823
Notes payable, net of discounts of $2,624,984 as of December 31, 2017 and $1,145,849 as of December 31, 2016	4,461,160	1,878,107
Notes payable - related parties	270,000	170,000
Derivative liability	5,939,600	1,927,752
Current portion of long term loan	4,221	12,395
Total current liabilities	13,409,345	8,721,324
Series C preferred stock liability, net of discounts of $101,808 at December 31, 2017 and $0 as of December 31, 2016	598,192
Long term loan		4,221
Acquisition payable	155,000	155,000
Total liabilities	14,162,537	8,880,545
COMMITMENTS AND CONTINGENCIES
Shareholders' deficit
Super AA super voting preferred stock, $0.001 par value; 1,000,000 authorized and 5,000 and 1,000 issued and outstanding at December 31, 2017 and December 31, 2016	5
Series B convertible preferred stock, $0.0001 par value; 50,000 shares authorized, 0 shares issued and outstanding at December 31, 2017 and December 31, 2016
Common stock, $.0001 par value; 500,000,000 shares authorized; 316,951,712 and 134,336,637 shares issued and outstanding as of December 31, 2017 and December 31, 2016	31,692	13,434
Additional paid-in capital	19,604,016	9,800,553
Stock subscriptions	(1,570)	(1,570)
Accumulated deficit	(29,184,443)	(18,374,283)
Total shareholders' deficit	(9,550,300)	(8,561,866)
Total liabilities and shareholders' deficit	$ 4,612,237	$ 318,679

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Discounts on current notes payable	$ 2,624,984	$ 1,145,849
Super AA super voting preferred stock, par value	$ 0.001	$ 0.001
Super AA super voting preferred stock, shares authorized	1,000,000	1,000,000
Super AA super voting preferred stock, shares issued	5,000	1,000
Super AA super voting preferred stock, shares outstanding	5,000	1,000
Series B convertible preferred stock, par value	$ 0.0001	$ 0.0001
Series B convertible preferred stock, shares authorized	50,000	50,000
Series B convertible preferred stock, shares issued	0	0
Series B convertible preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	316,951,712	134,336,637
Common stock, shares outstanding	316,951,712	134,336,637
Series C Preferred Stock [Member]
Series C preferred stock liability, net of discounts	$ 101,808	$ 0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Operating expenses	$ 4,603,886	$ 5,410,923
Loss from operations	(4,603,886)	(5,410,923)
Other income (expense)
Change in fair value of derivative liability	(2,982,543)	2,853,291
Gain on settlement of debt	80,294	124,888
Gain (loss) on extinguishment of debt	2,485,277	(488,149)
Interest expense, net	(5,789,302)	(2,394,779)
Total other income (expense)	(6,206,274)	95,251
Loss before income taxes	(10,810,160)	(5,315,672)
Provision for income taxes
Net loss	$ (10,810,160)	$ (5,315,672)
Basic and diluted loss per share	$ (0.04)	$ (0.05)
Weighted average common share outstanding:
Basic and diluted	242,090,416	117,405,894

Consolidated Statement of Stock

Consolidated Statement of Stockholders Deficit - USD ($)	Series AA Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Common Stock Subscription Receivable [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2015		$ 10,479	$ 3,773,642	$ (1,570)	$ (13,058,611)	$ (9,276,060)
Balance, shares at Dec. 31, 2015	1,000	104,803,401
Share issued for services		$ 990	2,363,981			2,364,971
Share issued for services, shares		9,888,760
Shares issued for conversion of notes payable and accrued interest		$ 947	1,956,770			1,957,717
Shares issued for conversion of notes payable and accrued interest, shares		9,476,582
Units issued for conversion of notes payable and accrued interest		$ 123	308,485			308,608
Units issued for conversion of notes payable and accrued interest,shares		1,226,229
Value of warrants issued with note payable			40,000			40,000
Shares issued for cash		$ 57	107,022			107,079
Shares issued for cash, shares		566,327
Units issued for cash		$ 797	1,127,953			1,128,750
Units issued for cash,shares		7,968,721
Shares issued with notes payable		$ 14	11,066			11,080
Shares issued with notes payable, shares		140,000
Shares issued on extension of notes payable		$ 27	111,634			111,661
Shares issued on extension of notes payable, shares		266,617
Net loss					(5,315,672)	(5,315,672)
Balance at Dec. 31, 2016		$ 13,434	9,800,553	(1,570)	(18,374,283)	(8,561,866)
Balance, shares at Dec. 31, 2016	1,000	134,336,637
Private placement units issued for cash		$ 4,242	1,286,008			1,290,250
Private placement units issued for cash, shares		42,434,151
Preferred stock issued for cash	$ 5					5
Preferred stock issued for cash, shares	4,000
Share issued for services		$ 369	203,937			204,306
Share issued for services, shares		3,698,022
Shares issued with lock-up agreements		$ 38	25,232			25,270
Shares issued with lock-up agreements, shares		379,294
Shares issued for conversion of notes payable and accrued interest		$ 12,315	4,963,635			4,975,950
Shares issued for conversion of notes payable and accrued interest, shares		123,163,542
Private placement units issued for conversion of notes payable and accrued interest		$ 337	66,029			66,366
Private placement units issued for conversion of notes payable and accrued interest, shares		3,370,041
Shares issued related to debt extinguishment and settlement		$ 214	119,068			119,282
Shares issued related to debt extinguishment and settlement, shares		2,142,387
Shares issued for repayment of accrued liability		$ 673	235,008			235,681
Shares issued for repayment of accrued liability, shares		6,725,000
Valuation of stock options issued for services			1,139,403			1,139,403
Valuation of warrants issued for services			71,113			71,113
Valuation of warrants issued with preferred stock			101,808			101,808
Value of warrants issued with note payable			83,453			83,453
Valuation of stock options issued in exchange of deferred compensation			1,467,311			1,467,311
Shares issued for cash		$ 5,050
Shares issued for cash, shares		250,000
Shares issued with notes payable		$ 95,597
Shares issued with notes payable, shares		2,142,387
Shares issued on exercise of warrants		$ 25	5,025			5,050
Shares issued on exercise of warrants,shares		250,000
Private placement units issued for conversion of notes payable and accrued interest		$ 400	112,738			113,138
Private placement units issued for conversion of notes payable and accrued interest,shares		4,002,953
Shares returned on settlement of debt		$ (18)	(10,276)			(10,294)
Shares returned on settlement of debt,shares		(180,274)
Net loss					(10,810,160)	(10,810,160)
Balance at Dec. 31, 2017	$ 5	$ 31,692	$ 19,604,016	$ (1,570)	$ (29,184,443)	$ (9,550,300)
Balance, shares at Dec. 31, 2017	5,000	316,951,712

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Operating activities:
Net loss	$ (10,810,160)	$ (5,315,672)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization expense	14,761	15,833
Fair value of equity issued for services	1,414,823	2,364,971
Non-cash interest and fees	3,400,511	1,290,383
Amortization of note discount and original issue discount	2,165,710	1,055,316
Change in fair value of derivative liability	2,982,543	(2,853,291)
(Gain) loss on extinguishment of debt	(2,485,277)	488,149
Gain on settlement of debt	(80,294)	(124,888)
Changes in assets and liabilities:
Prepaid expenses and other current assets	263,321	86,012
Accounts payable and accrued expenses	144,292	530,853
Net cash used in operating activities	(2,989,770)	(2,462,334)
Investing activities:
Acquisition of patents	(3,000,000)
Net cash used in investing activities	(3,000,000)
Financing activities:
Proceeds from the issuance of notes payable	4,047,000	1,491,778
Proceeds from issuance of notes payable- related parties	100,000
Proceeds from short term advances	26,000	12,618
Proceeds from exercise of warrants	5,050
Proceeds from issuance of preferred stock	700,005
Repayments on short term advances	(11,500)	(10,300)
Proceeds from issuance of common stock	1,290,250	1,235,829
Payment on notes payable	(120,000)	(166,500)
Payment on notes payable- related parties		(75,000)
Payment against long term loan	(12,395)	(12,031)
Net cash provided by financing activities	6,024,410	2,476,394
Net increase in cash	34,640	14,060
Cash, beginning of year	55,533	41,473
Cash, end of year	90,173	55,533
Supplemental disclosure of cash flow information:
Cash paid for interest	33,868	27,088
Cash paid for income taxes
Non Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	1,582,349	711,098
Settlement of liabilities by issuance of common stock	354,964	61,600
Notes payable issued for services		100,000
Notes payable issued on acquisition of patents	1,500,000
Deferred compensation converted to stock options	1,467,311
Accrued interest converted to notes payable	$ 39,570	$ 18,448

Nature of Business and Summary

Nature of Business and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Summary of Significant Accounting Policies	Note 1 - Nature of Business and Summary of Significant Accounting Policies Endonovo Therapeutics, Inc. and Subsidiaries (the “Company” or “ETI”) is primarily focused in the business of biomedical research and development, particularly in regenerative medicine, which has included the development of the proprietary non-invasive electrocuetical device and intellectual property licensing and commercialization. On January 22, 2014 Hanover Portfolio Acquisitions, Inc. (the “Company”) received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company’s Certificate of Incorporation to change the name of the Company from “Hanover Portfolio Acquisitions, Inc.” to “Endonovo Therapeutics, Inc.” The name change was affected pursuant to a Certificate of Amendment (the “Certificate of Amendment”), filed with the Secretary of State of Delaware on January 24, 2014. Basis of Presentation and Principles of Consolidation The consolidated financial statements of the Company include the accounts of ETI, IP Resources International, Inc., Aviva Companies Corporation, and WeHealAnimals, Inc. All significant intercompany accounts and transactions are eliminated in consolidation. Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has recurring net losses, negative cash flows from operations and working capital deficits. The Company has raised approximately $4.4 million in debt and equity financing for the year ended December 31, 2017. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its common stock and is seeking out profitable companies. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates. Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. At December 31, 2017, cash and cash equivalents did not exceed FDIC limits. Property, plant and equipment Property, plant and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range between five and seven years. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss recorded to the consolidated statements of operations. Impairment of Long-lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows generated from the asset group to the recorded value of the asset group. If impairment is indicated, the asset is written down to its estimated fair value. Stock-Based Compensation The Company measures stock-based compensation cost at the grant date based on the fair value of the award and recognizes it as expense, net of estimated forfeitures, over the vesting or service period, as applicable, of the stock award using the straight-line method. When our common stock is thinly traded, we have made estimates of the fair value of the common stock based not only on market prices but other factors such as financial condition and results of operations. The Company measured stock-based compensation using the Black-Scholes option valuation model using the following assumptions: December 31, 2017 Expected term 2 - 5 years Exercise price $0.0216 - $0.2669 Expected volatility 184% - 217% Expected dividends None Risk-free interest rate 1.50% - 1.87% Forfeitures None Income Taxes The Company records a tax provision for the anticipated tax consequences of its reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and income tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company has adopted ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company has determined that the adoption did not result in the recognition of any liability for unrecognized tax benefits and that there are no unrecognized tax benefits that would, if recognized, affect the Company’s effective tax rate. Net Income (Loss) per Share Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive. Research and Development Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development Fair Value of Financial Instruments Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company’s balance sheet contains derivative liability that is recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Sholes option valuation model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2017 and 2016: Fair Value Measurements at December 31, 2017 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 5,939,600 $ 5,939,600 Total $ - $ - $ 5,939,600 $ 5,939,600 Fair Value Measurements at December 31, 2016 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 1,927,752 $ 1,927,752 Total $ - $ - $ 1,927,752 $ 1,927,752 The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2017 and 2016: Liability Balance December 31, 2015 $ 3,973,542 Increase in Derivative Liability resulting from Issuance of convertible debt 2,525,515 Decrease in Derivative Liability resulting from Settlements by debt extinguishment (1,718,013 ) Decrease in Derivative Liability resulting from Change in estimated fair value (2,853,292 ) Balance December 31, 2016 1,927,752 Increase in Derivative Liability resulting from Issuance of convertible debt 9,185,674 Decrease in Derivative Liability resulting from Settlements by debt extinguishment (8,156,369 ) Increase in Derivative Liability resulting from Change in estimated fair value 2,982,543 Balance December 31, 2017 $ 5,939,600 Derivative Liability The Company issued Variable Debentures during the years ended December 31, 2017 and 2016, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in a derivative liability. The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions: For Year Ending December 31, 2017 2016 Expected term 1 year 1 year - 2 years Exercise price $0.0063-$0.385 $0.0113-$0.81 Expected volatility 163%-201% 176%-276% Expected dividends None None Risk-free interest rate 0.79%-1.76% 0.45%-1.06% Forfeitures None None The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control, and the assessment of volatility. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases. Preferred Stock The Company elects to accrete the difference between the redemption value and carrying value of outstanding preferred stock over the period from the date of issuance to the earliest redemption date using the effective interest method. Recent Accounting Standard Updates In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company does not expect the adoption of this standard to significantly impact its consolidated financial statements. In 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments Restricted Cash In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory On January 1, 2017, we adopted ASU 2016-09, Compensation - Stock Compensation In January 2017, the FASB issued ASU 2017-01, Business Combinations (“ASU 2017-01”) which provided new guidance clarifying the definition of a business for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new standard is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted for transactions that occurred before the issuance date or effective date of the standard if the transactions were not reported in financial statements that have been issued or made available for issuance. Upon early adoption, the standard did not impact how we assess acquisitions (or disposals) of assets or businesses. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) that simplifies the test for goodwill impairment by eliminating step two from the goodwill impairment test. Under the new guidance, an entity should recognize an impairment charge for the amount based on the excess of a reporting unit’s carrying amount over its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. For public companies, the guidance is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019 on a prospective basis, and earlier adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. We early adopted this guidance during 2017, and the adoption did not impact our financial statements.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Note 2 - Property and Equipment The following is a summary of equipment, at cost, less accumulated depreciation at December 31, 2017 and 2016: As of December 31, 2017 2016 Autos $ 64,458 $ 64,458 Medical equipment 5,000 5,000 Other equipment 8,774 8,774 78,232 78,232 Less accumulated depreciation 77,168 62,407 $ 1,064 $ 15,825 Depreciation expense for the years ended December 31, 2017 and 2016 was $14,761 and $15,833, respectively.

Patents

Patents	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Note 3 – Patents In December 2017, we acquired from RGN a patent portfolio for $4,500,000 as part of a settlement agreement. The oldest patents expire in 2024. The patent portfolio is amortized through 2024. The following is a summary of patents less accumulated amortization at December 31, 2017 and 2016: December 31, 2017 2016 Patents $ 4,500,000 $ - Less accumulated amortization - - $ 4,500,000 $ - There is no amortization expense associated with patents for the years ended December 31, 2017 and 2016. The estimated future amortization expense related to patents as of December 31, 2017 is as follows: Year Ended December 31. Amount 2018 $ 646,910 2019 646,910 2020 646,910 2021 646,910 2022 646,910 Thereafter 1,265,450 Total $ 4,500,000

Notes Payable and Long Term Loa

Notes Payable and Long Term Loan	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Notes Payable and Long Term Loan	Note 4 - Notes payable and Long Term Loan Notes Payable In October 2013, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000, one unit. The notes bear interest at 10% per annum and were due and payable with accrued interest one year from issuance. Also, the Company agreed to issue 125,000 shares of its common stock for each unit. In July 2014, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000, one unit. The notes bear interest at 10% per annum and were due and payable with accrued interest one year from issuance. Also, the Company agreed to issue 50,000 shares of its common stock for each unit. In October 2014, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000, one unit. The notes bear interest at 10% per annum and were due and payable with accrued interest one year from issuance. Also, the Company agreed to issue 50,000 shares of its common stock for each unit. In August 2015, the Company initiated a private placement for up to $500,000 of financing by the issuance of notes payable at a minimum of $25,000, one unit. The notes bear interest at 10% per annum and were due and payable with accrued interest one year from issuance. Also, the Company agreed to issue 100,000 shares of its common stock for each unit. During the years ended December 31, 2017 and 2016, the Company did not issue notes in connection with these private placements. As of December 31, 2017 and 2016, notes payable outstanding under these private placements are $919,903 and $1,075,500, respectively. Of these amounts, $919,903 and $1,065,000 of the outstanding balance on these notes are past maturity at December 31, 2017 and 2016, respectively. During the years ended December 31, 2017 and 2016, the Company issued Convertible Debentures (“Variable Debentures”) in amounts of $4,137,070 and $1,744,416 for cash of $3,947,000 and $1,421,778 with ori During the year ended December 31, 2017, the Company entered into a $1,500,000 note payable with an unrelated party in connection with the acquisition of patents. The note bears interest at 8% per year and matures in November 2018. At December 31, 2017, $1,500,000 remained outstanding on this note. During the year ended December 31, 2017, the Company entered into a $100,000 note payable with an unrelated party and issued a warrant for up to 500,000 shares of common stock at a value of $21,204 in connection with this note. The note bears interest at 10% per year and matures in February 2018. At December 31, 2017, $100,000 remained outstanding on this note. During the year ended December 31, 2016, the Company entered into two notes payable agreements for $70,000 in aggregate with an unrelated party and issued 140,000 shares in connection with these notes. The notes bear interest at 10% per year and matured in May 2017. At December 31, 2017 and 2016, $0 and $60,000 were outstanding on these notes. As of December 31, 2017, the Company had notes payable to related parties amounting to $270,000. Refer to Note 6 – Related Party Transactions. As of December 31, 2017 2016 Notes payable at beginning of period $ 3,193,956 $ 2,333,751 Notes payable issued 5,837,070 1,776,895 Default interest added to note payable - 62,500 Settlements on note payable (95,597 ) (55,000 ) Repayments of notes payable in cash (96,000 ) (241,500 ) Less amounts converted to stock (1,483,285 ) (682,690 ) Notes payable at end of period 7,356,144 3,193,956 Less debt discount (2,624,984 ) (1,145,849 ) $ 4,731,160 $ 2,048,107 Notes payable issued to related parties $ 270,000 $ 170,000 Notes payable issued to non-related parties $ 4,461,160 $ 1,878,107 The maturity dates on the notes payable are as follows: Twelve months ending, Non-related parties Related parties Total Past due $ 1,122,403 $ 170,000 $ 1,292,403 December 31, 2018 5,963,741 100,000 6,063,741 Total $ 7,086,144 $ 270,000 $ 7,356,144 Long Term Loan The Company has financed the purchase of an automobile. The maturity dates on the loan are as follows: Maturity dates of long term debt Twelve months ending, December 31, 2018 $ 4,221 $ 4,221 Current portion $ 4,221 Acquisition Payable In connection with the Company’s acquisition of IPR in 2012, IPR recorded a $155,000 long-term acquisition payable for costs that were not paid at closing. These payable is non-interest bearing and IPR agreed to make payments up to 25% of the proceeds from any private placement or gross profits earned by IPR until the obligation is satisfied. The percentage of the proceeds to be paid is at the sole discretion of IPR’s Chief Executive Officer and the ex-Chief Executive Officer of the Company based on the liquidity of the Company. Effective Interest Rate During the year ended December 31, 2017 and 2016, the Company’s effective interest rate was 222% and 89%, respectively.

Shareholders' Deficit

Shareholders' Deficit	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Shareholders' Deficit	Note 5 - Shareholders’ Deficit Preferred Stock The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows: Number of Shares Number of Shares Outstanding Par Liquidation Authorized at December 31, 2017 Value Value Series AA 1,000,000 5,000 $ 0.0001 $ - Preferred Series B 50,000 - $ 0.0001 $ 100 Preferred Series C 8,000 700 $ 0.0001 $ 1,000 Undesignated 3,942,000 - - - Series AA Preferred Shares On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.0001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof. Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. Upon liquidation, dissolution and winding up of the Corporation, whether voluntary or involuntary, the holders of the Series AA Super Voting Preferred Stock then outstanding shall not be entitled to receive out of the assets of the Corporation, whether from capital or earnings available for distribution, any amounts which will be otherwise available to and distributed to the Common Stockholders. As of December 31, 2017 and 2016, there were 5,000 and 1,000 shares of Series AA Preferred stock outstanding. Series B Convertible Preferred Stock At December 31, 2017, there are 50,000 shares of Series B Convertible Preferred Stock designated as Series B (“Series B”) which are authorized and convertible into a like amount of common shares. None of the Series B have been issued or are outstanding at December 31, 2017. Series C Secured Redeemable Preferred Stock During the year ended December 31, 2017, the Company filed a certificate of designation (the “Designation”) for 8,000 shares of Series C Secured Redeemable Preferred Stock (“C Preferred”). Each share of the C Preferred, which has a stated value of $1,000 per share and par value of $0.0001 per share, is entitled to a $20.00 quarterly dividend commencing March 21, 2018 and each quarter thereafter and is to be redeemed for the stated value plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. Since the C Preferred is mandatorily payable, the obligation has been included in long term liabilities on the consolidated balance sheet as of December 31, 2017. The C Preferred does not have any rights to vote with the common stock. The Company’s obligation to redeem the C Preferred is secured by a security interest in the RGN Assets. The Preferred Stock Series C holders have liquidation preferences over the common stock holders. As of December 31, 2017, the Company has sold 700 shares of C Preferred in units comprised of shares of C Preferred and common stock purchase warrants exercisable into up to 2,725,269 shares of common stock for consideration of $700,000. The warrants are valued at $101,808 at December 31, 2017 and are recorded as a discount to the preferred stock liability on the consolidated balance sheet. Common Stock During the year ended December 31, 2017, the Company issued pursuant to a private placement offering 46,437,104 shares of common stock and the same number of warrants for cash of $1,290,250 and conversion of notes and accrued interest in the amount of $113,138. The Company also issued 123,163,542 shares of common stock for the conversion of notes and accrued interest in the amount of $4,975,949. During the year ended December 31, 2017, the Company issued 379,294 shares of common stock valued at $25,270 related to the extension of outstanding notes and lock-up agreements; 2,142,387 shares valued at $119,282 were issued in connection with $95,597 notes payable; 6,725,000 shares valued at $235,681 were issued in connection with a settlement entered into in 2016; 250,000 shares were issued for cash of $5,050 as a result of a common stock warrant exercise; and 180,274 shares were cancelled valued at $10,294 related to a settlement agreement. The Company had entered into consulting agreements with various consultants for service to be provided to the Company. The agreements stipulated a monthly fee and a certain number of shares that the consultant vests in over the term of the contract. The consultant was issued a prorated number of shares of common stock at the beginning of the contract, which the consultant earned over a three-month period. At the anniversary of each quarter, the consultant was issued a new allotment of common stock during the first 3 years of engagement. In accordance with ASC 505-50 – Equity-Based Payment to Non-Employees, the common stock shares issued to the consultant were valued upon their vesting, with interim estimates of value as appropriate during the vesting period. During the years ended December 31, 2017 and 2016, the Company issued 3,698,022 shares of common stock with a value of $204,306 and 2,775,000 shares of common stock with a value of $953,250, respectively, related to these consulting agreements. During the year ended December 31, 2016, the Company also issued 7,113,760 shares of common stock with a value of $1,411,722 for additional services and fees. During the year ended December 31, 2016, the Company issued pursuant to a private placement offering 9,194,940 shares of common stock and the same number of warrants for cash of $1,128,750 and conversion of notes and accrued interest in the amount of $308,608. The Company also issued 566,327 shares of common stock for cash of $107,079 and 9,476,582 shares of common stock for the conversion of notes and accrued interest in the amount of $1,957,717. Also, during the year ended December 31, 2016, the Company issued 266,617 shares of common stock valued at $111,661 related to the extension of outstanding notes and lock-up agreements and 140,000 shares valued at $11, 080 were issued in connection with $70,000 notes payable. The Variable Debentures issued by the Company each have a provision requiring the Company to reserve a variable amount of shares of common stock for when the holder of the Variable Debenture converts. As of December 31, 2017, the Company has reserved approximately 147,868,000 of common shares related to the outstanding debentures. Stock Options During the year ended December 31, 2017, the Company granted stock options to independent contractors exercisable into up to 25,272,305 shares of common stock with exercise prices ranging from $0.0269 to $0.054 per share, lives ranging from three to ten years, and cashless exercise rights and were valued at $1,139,403 using the Black Scholes option pricing model. The stock options vested on grant and were expensed in full during the year ended December 31, 2017. In addition, during the year ended December 31, 2017, the Company issued stock options to independent contractors exercisable into up to 67,931,064 shares of common stock in exchange for the conversion of $1,467,311 of deferred compensation due to the independent contractors. These options have an exercise price of $0.0216 per share, a three-year life and cashless exercise rights. These options vested on grant. The weighted average grant date fair value of stock options issued during the year ended December 31, 2017 was $0.03 per share. The balance of all stock options outstanding as of December 31, 2017 is as follows: Weighted Average Weighted Average Exercise Price Remaining Contractual Aggregate Intrinsic Options Per Share Term (years) Value Outstanding at January 1, 2017 - $ - Granted 93,203,369 $ 0.029 Cancelled - $ - Exercised - $ - Outstanding at December 31, 2017 93,203,369 $ 0.029 3.96 $ 2,721,538 Exercisable at December 31, 2017 93,203,369 $ 0.029 3.96 $ 2,721,538 Outstanding Exercisable Weighted Average Weighted Weighted Range of Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life Price Exercisable Price Options $ 0.0540 19,250,000 9.29 $ 0.0540 19,250,000 $ 0.0540 $ 0.0269 6,022,305 2.72 $ 0.0269 6,022,305 $ 0.0269 $ 0.0216 67,931,064 2.55 $ 0.0216 67,931,064 $ 0.0216 93,203,369 3.96 $ 0.029 93,203,369 $ 0.029 Warrants During the year ended December 31, 2017, in conjunction with the sale of Common Stock, the Company issued three-year and five-year common stock purchase warrants to acquire up to 46,437,100 shares of common stock with exercise prices ranging from $0.0188 to $1.00 per share. In addition, during the year ended December 31, 2017, the Company issued two-year common stock purchase warrants to acquire up to 2,300,000 shares of common stock valued at $83,453 with an exercise prices ranging from $0.0508 to $0.25 in conjunction with the issuance of notes payable; five-year common stock purchase warrants to acquire up to 1,100,678 shares of common stock valued at $71,113 for services provided with exercise prices ranging from $0.096 to $0.267 per share; and two-year common stock purchase warrants to acquire up to 2,725,269 shares of common stock with exercise prices ranging from $0.047 to $0.058 in conjunction with the issuance of preferred stock. During the year ended December 31, 2016, in conjunction with the sale of Common Stock, the Company issued five-year common stock purchase warrants to acquire up to 9,194,940 shares of common stock with exercise prices ranging from $0.0825 to $0.90 per share. In March 2016, the Company issued a two-year common stock purchase warrant exercisable into up to 300,000 shares of common stock with an exercise price of $0.81 for services provided by a consultant. The value of these warrants was recorded as non-cash expense in an amount of $40,000 using the Black Sholes Option pricing method. A summary of the status of the warrants granted under these agreements at December 31, 2017, and changes during the year then ended is presented below: Outstanding Warrants Weighted Average Exercise Price Shares Per Share Outstanding at January 1, 2017 9,494,940 $ 0.33 Granted 52,563,052 $ 0.31 Cancelled - $ - Exercised (250,000 ) $ 0.02 Outstanding at December 31, 2017 61,807,992 $ 0.31 Exercisable at December 31, 2017 61,807,992 $ 0.31 Outstanding Exercisable Weighted Average Weighted Weighted Range of Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life Price Exercisable Price Warrants $ 0.0165-0.0469 15,019,850 3.44 $ 0.033 15,019,850 $ 0.033 $ 0.0508-0.10 21,438,396 3.56 $ 0.075 21,438,396 $ 0.075 $ 0.108-0.239 6,010,037 3.60 $ 0.161 6,010,037 $ 0.161 $ 0.25-0.48 2,862,687 2.56 $ 0.276 2,862,687 $ 0.276 $ 0.5623-1.00 16,477,022 2.77 $ 0.938 16,477,022 $ 0.938 61,807,992 3.32 $ 0.313 61,807,992 $ 0.313 As of December 31, 2017, the Company has 500,000,000 shares of common stock authorized. After the exercise of stock options and warrants and the conversion of variable rate debentures, the Company could potentially have a shortfall of common stock. Should there be a shortfall in common stock, the shareholders of the Company would need to approve an increase in the authorized common stock to an amount sufficient to satisfy such exercises and conversions or reclassify the obligations to liabilities payable in some form other than common stock.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 6 – Related Party Transactions Executives of the Company have agreed to defer compensation until cash flow improves. As of December 31, 2017 and 2016, the balances of their deferred compensation was $922,395 and $1,861,327 which reflects $894,394 accrual of deferred compensation, $1,173,297 stock options/warrants and the conversion of $660,000 of deferred compensation into stock options of the Company during the year ended December 31, 2017 and $720,000 accrual of deferred compensation and $533,103 cash repayments during the year ended December 31, 2016. From time-to-time Executives of the Company advance monies to the Company to cover costs. During the years ended December 31, 2017 and 2016, officers advanced $26,000 and $12,618 of funds to the Company of which $11,500 and $10,300 were repaid during the years then ended. Also, during the years ended December 31, 2017 and 2016 accrued interest was repaid in an amount of $22,100 and $0, respectively. The balance of short-term advances Executives of the Company at December 31, 2017 and 2016 was $20,323 and $5,823, respectively. During the years ended December 31, 2017 and 2016, an Executive of the Company entered into note payable agreements for $100,000 and $50,000, respectively. During the year ended December 31, 2016, the Company repaid the principal and interest of a $75,000 note payable to another Executive. At December 31, 2017 and 2016, notes payable remain outstanding to one Executive of the Company, in the amounts of $270,000 and $170,000, respectively. At December 31, 2017 and 2016, accrued interest on these notes payable totaled $21,983 and $20,284, respectively, and are included in accounts payable and accrued expenses on the consolidated balance sheet.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Note 7 - Income taxes The Company files income tax returns with the Internal Revenue Service (“IRS”) and various state jurisdictions. For jurisdictions in which tax filings are prepared, the Company is subject to income tax examinations by state tax authorities and federal tax authorities for all tax years. The deferred tax assets are mainly comprised of net loss carryforwards. As of December 31, 2017, the Company had approximately $14,000,000 of federal net operating loss carryforwards that it can use to offset a certain amount of taxable income in the future. These federal net operating loss carryforwards begin to expire in 2029. The resulting deferred tax asset is offset by a 100% valuation allowance due to the uncertainty of its realization. A reconciliation of the provision for income tax expense with the expected income tax computed by applying the federal statutory income tax rate to income before provision for income taxes was as follows for the years ended December 31, 2017 and 2016: 2017 2016 Income tax computed at federal statutory tax rate -34.0 % -34.0 % Change in valuation allowance 39.8 % 39.8 % State taxes, net of federal benefit -5.8 % -5.8 % Total 0.0 % 0.0 % The primary difference between income tax expense attributable to continuing operations and the amount of income tax expense that would result from applying domestic federal statutory rates to income before provision for income taxes relates to the change in the valuation allowance. The Company has adopted the accounting standards that clarify the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. Interest and penalties totaled $0 for the years ended December 31, 2017 and 2016.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 8 - Commitments and Contingencies Legal matters The Company may become involved in various legal proceedings in the normal course of business.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 9 - Subsequent Events. Subsequent to December 31, 2017, an aggregate of 100,000 shares of restricted common stock and 6,200,000 common stock purchase warrants were issued as compensation to independent contractors. Subsequent to December 31, 2017, the Company raised $60,000 from 3 investors as part of a Private Placement and issued 1,561,950 shares of restricted common stock and 1,561,950 common stock purchase warrants. Subsequent to December 31, 2017, the Company converted $477,491 of principal and $36,039 of accrued interest in Variable Debentures outstanding at December 31, 2017 through the issuance of 19,327,397 of restricted shares of common stock. Subsequent to December 31, 2017, the Company issued 17,003 of restricted common stock related to lock-up agreements and $195,000 of cash was received from the issuance of 1350 shares of Preferred B and 60 shares of Preferred C Stock. In addition, the Company issued warrants exercisable into up to 5,076,111 shares of common stock related to the issuance of the Preferred B and Preferred C Stock. Subsequent to December 31, 2017, the Company received cash of $625,000 in connection with three notes issued for a total of $705,370 and issued a warrant to purchase up to 2,000,000 shares of common stock related to one of the notes. Under the terms of one of the notes, the Company issued 3,387,534 shares of common stock to the lender which are returnable to the Company if the note is fully repaid or fulfilled by its maturity date. As a result of these issuances the total number of common shares outstanding is 341,345,596, Preferred B shares outstanding is 1350 and Preferred C shares outstanding is 760.

Nature of Business and Summar16

Nature of Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The consolidated financial statements of the Company include the accounts of ETI, IP Resources International, Inc., Aviva Companies Corporation, and WeHealAnimals, Inc. All significant intercompany accounts and transactions are eliminated in consolidation.
Going Concern	Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has recurring net losses, negative cash flows from operations and working capital deficits. The Company has raised approximately $4.4 million in debt and equity financing for the year ended December 31, 2017. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its common stock and is seeking out profitable companies.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.
Cash and Cash Equivalents	Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. At December 31, 2017, cash and cash equivalents did not exceed FDIC limits.
Property Plant and Equipment	Property, plant and equipment Property, plant and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range between five and seven years. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss recorded to the consolidated statements of operations.
Impairment of Long-lived Assets	Impairment of Long-lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted future cash flows generated from the asset group to the recorded value of the asset group. If impairment is indicated, the asset is written down to its estimated fair value.
Stock- Based Compensation	Stock-Based Compensation The Company measures stock-based compensation cost at the grant date based on the fair value of the award and recognizes it as expense, net of estimated forfeitures, over the vesting or service period, as applicable, of the stock award using the straight-line method. When our common stock is thinly traded, we have made estimates of the fair value of the common stock based not only on market prices but other factors such as financial condition and results of operations. The Company measured stock-based compensation using the Black-Scholes option valuation model using the following assumptions: December 31, 2017 Expected term 2 - 5 years Exercise price $0.0216 - $0.2669 Expected volatility 184% - 217% Expected dividends None Risk-free interest rate 1.50% - 1.87% Forfeitures None
Income Taxes	Income Taxes The Company records a tax provision for the anticipated tax consequences of its reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and income tax credit carryforwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company has adopted ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company has determined that the adoption did not result in the recognition of any liability for unrecognized tax benefits and that there are no unrecognized tax benefits that would, if recognized, affect the Company’s effective tax rate.
Net Income (Loss) Per Share	Net Income (Loss) per Share Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive.
Research and Development	Research and Development Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development
Fair Value of Financial Instruments	Fair Value of Financial Instruments Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company’s balance sheet contains derivative liability that is recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Sholes option valuation model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2017 and 2016: Fair Value Measurements at December 31, 2017 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 5,939,600 $ 5,939,600 Total $ - $ - $ 5,939,600 $ 5,939,600 Fair Value Measurements at December 31, 2016 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 1,927,752 $ 1,927,752 Total $ - $ - $ 1,927,752 $ 1,927,752 The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2017 and 2016: Liability Balance December 31, 2015 $ 3,973,542 Increase in Derivative Liability resulting from Issuance of convertible debt 2,525,515 Decrease in Derivative Liability resulting from Settlements by debt extinguishment (1,718,013 ) Decrease in Derivative Liability resulting from Change in estimated fair value (2,853,292 ) Balance December 31, 2016 1,927,752 Increase in Derivative Liability resulting from Issuance of convertible debt 9,185,674 Decrease in Derivative Liability resulting from Settlements by debt extinguishment (8,156,369 ) Increase in Derivative Liability resulting from Change in estimated fair value 2,982,543 Balance December 31, 2017 $ 5,939,600
Derivative Liability	Derivative Liability The Company issued Variable Debentures during the years ended December 31, 2017 and 2016, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in a derivative liability. The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions: For Year Ending December 31, 2017 2016 Expected term 1 year 1 year - 2 years Exercise price $0.0063-$0.385 $0.0113-$0.81 Expected volatility 163%-201% 176%-276% Expected dividends None None Risk-free interest rate 0.79%-1.76% 0.45%-1.06% Forfeitures None None The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control, and the assessment of volatility. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.
Preferred Stock	Preferred Stock The Company elects to accrete the difference between the redemption value and carrying value of outstanding preferred stock over the period from the date of issuance to the earliest redemption date using the effective interest method.
Recent Accounting Standard Updates	Recent Accounting Standard Updates In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company does not expect the adoption of this standard to significantly impact its consolidated financial statements. In 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments Restricted Cash In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory On January 1, 2017, we adopted ASU 2016-09, Compensation - Stock Compensation In January 2017, the FASB issued ASU 2017-01, Business Combinations (“ASU 2017-01”) which provided new guidance clarifying the definition of a business for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new standard is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted for transactions that occurred before the issuance date or effective date of the standard if the transactions were not reported in financial statements that have been issued or made available for issuance. Upon early adoption, the standard did not impact how we assess acquisitions (or disposals) of assets or businesses. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) that simplifies the test for goodwill impairment by eliminating step two from the goodwill impairment test. Under the new guidance, an entity should recognize an impairment charge for the amount based on the excess of a reporting unit’s carrying amount over its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. For public companies, the guidance is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019 on a prospective basis, and earlier adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. We early adopted this guidance during 2017, and the adoption did not impact our financial statements.

Nature of Business and Summar17

Nature of Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Measured Stock- Based Compensation	The Company measured stock-based compensation using the Black-Scholes option valuation model using the following assumptions: December 31, 2017 Expected term 2 - 5 years Exercise price $0.0216 - $0.2669 Expected volatility 184% - 217% Expected dividends None Risk-free interest rate 1.50% - 1.87% Forfeitures None
Schedule of Balances of Liabilities Measured at Fair Value	The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2017 and 2016: Fair Value Measurements at December 31, 2017 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 5,939,600 $ 5,939,600 Total $ - $ - $ 5,939,600 $ 5,939,600 Fair Value Measurements at December 31, 2016 Using Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Identical Assets Inputs Inputs (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 1,927,752 $ 1,927,752 Total $ - $ - $ 1,927,752 $ 1,927,752
Schedule of Changes in the Liabilities with Significant Unobservable Inputs	The following table presents changes in the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2017 and 2016: Liability Balance December 31, 2015 $ 3,973,542 Increase in Derivative Liability resulting from Issuance of convertible debt 2,525,515 Decrease in Derivative Liability resulting from Settlements by debt extinguishment (1,718,013 ) Decrease in Derivative Liability resulting from Change in estimated fair value (2,853,292 ) Balance December 31, 2016 1,927,752 Increase in Derivative Liability resulting from Issuance of convertible debt 9,185,674 Decrease in Derivative Liability resulting from Settlements by debt extinguishment (8,156,369 ) Increase in Derivative Liability resulting from Change in estimated fair value 2,982,543 Balance December 31, 2017 $ 5,939,600
Schedule of Variable Debentures Black-Scholes Valuation Assumptions	The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions: For Year Ending December 31, 2017 2016 Expected term 1 year 1 year - 2 years Exercise price $0.0063-$0.385 $0.0113-$0.81 Expected volatility 163%-201% 176%-276% Expected dividends None None Risk-free interest rate 0.79%-1.76% 0.45%-1.06% Forfeitures None None

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Summary of Property, Plant and Equipment	The following is a summary of equipment, at cost, less accumulated depreciation at December 31, 2017 and 2016: As of December 31, 2017 2016 Autos $ 64,458 $ 64,458 Medical equipment 5,000 5,000 Other equipment 8,774 8,774 78,232 78,232 Less accumulated depreciation 77,168 62,407 $ 1,064 $ 15,825

Patents (Tables)

Patents (Tables)	12 Months Ended
	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents Less Accumulated Amortization	The following is a summary of patents less accumulated amortization at December 31, 2017 and 2016: December 31, 2017 2016 Patents $ 4,500,000 $ - Less accumulated amortization - - $ 4,500,000 $ -
Schedule of Estimated Future Amortization Expense	The estimated future amortization expense related to patents as of December 31, 2017 is as follows: Year Ended December 31. Amount 2018 $ 646,910 2019 646,910 2020 646,910 2021 646,910 2022 646,910 Thereafter 1,265,450 Total $ 4,500,000

Notes Payable and Long Term L20

Notes Payable and Long Term Loan (Tables)	12 Months Ended
	Dec. 31, 2017
Schedule of Note Payables	As of December 31, 2017 2016 Notes payable at beginning of period $ 3,193,956 $ 2,333,751 Notes payable issued 5,837,070 1,776,895 Default interest added to note payable - 62,500 Settlements on note payable (95,597 ) (55,000 ) Repayments of notes payable in cash (96,000 ) (241,500 ) Less amounts converted to stock (1,483,285 ) (682,690 ) Notes payable at end of period 7,356,144 3,193,956 Less debt discount (2,624,984 ) (1,145,849 ) $ 4,731,160 $ 2,048,107 Notes payable issued to related parties $ 270,000 $ 170,000 Notes payable issued to non-related parties $ 4,461,160 $ 1,878,107
Schedule of Maturity Dates of Notes Payable and Long Term Loan	The maturity dates on the notes payable are as follows: Twelve months ending, Non-related parties Related parties Total Past due $ 1,122,403 $ 170,000 $ 1,292,403 December 31, 2018 5,963,741 100,000 6,063,741 Total $ 7,086,144 $ 270,000 $ 7,356,144
Long-term Debt [Member]
Schedule of Maturity Dates of Notes Payable and Long Term Loan	The maturity dates on the loan are as follows: Maturity dates of long term debt Twelve months ending, December 31, 2018 $ 4,221 $ 4,221 Current portion $ 4,221

Shareholders' Deficit (Tables)

Shareholders' Deficit (Tables)	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Schedule of Preferred Stock	The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows: Number of Shares Number of Shares Outstanding Par Liquidation Authorized at December 31, 2017 Value Value Series AA 1,000,000 5,000 $ 0.0001 $ - Preferred Series B 50,000 - $ 0.0001 $ 100 Preferred Series C 8,000 700 $ 0.0001 $ 1,000 Undesignated 3,942,000 - - -
Schedule of Stock Options Outstanding	The balance of all stock options outstanding as of December 31, 2017 is as follows: Weighted Average Weighted Average Exercise Price Remaining Contractual Aggregate Intrinsic Options Per Share Term (years) Value Outstanding at January 1, 2017 - $ - Granted 93,203,369 $ 0.029 Cancelled - $ - Exercised - $ - Outstanding at December 31, 2017 93,203,369 $ 0.029 3.96 $ 2,721,538 Exercisable at December 31, 2017 93,203,369 $ 0.029 3.96 $ 2,721,538
Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range	Outstanding Exercisable Weighted Average Weighted Weighted Range of Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life Price Exercisable Price Options $ 0.0540 19,250,000 9.29 $ 0.0540 19,250,000 $ 0.0540 $ 0.0269 6,022,305 2.72 $ 0.0269 6,022,305 $ 0.0269 $ 0.0216 67,931,064 2.55 $ 0.0216 67,931,064 $ 0.0216 93,203,369 3.96 $ 0.029 93,203,369 $ 0.029
Schedule of Warrants Outstanding	A summary of the status of the warrants granted under these agreements at December 31, 2017, and changes during the year then ended is presented below: Outstanding Warrants Weighted Average Exercise Price Shares Per Share Outstanding at January 1, 2017 9,494,940 $ 0.33 Granted 52,563,052 $ 0.31 Cancelled - $ - Exercised (250,000 ) $ 0.02 Outstanding at December 31, 2017 61,807,992 $ 0.31 Exercisable at December 31, 2017 61,807,992 $ 0.31
Schedule of Warrants Exercise Price Range	Outstanding Exercisable Weighted Average Weighted Weighted Range of Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life Price Exercisable Price Warrants $ 0.0165-0.0469 15,019,850 3.44 $ 0.033 15,019,850 $ 0.033 $ 0.0508-0.10 21,438,396 3.56 $ 0.075 21,438,396 $ 0.075 $ 0.108-0.239 6,010,037 3.60 $ 0.161 6,010,037 $ 0.161 $ 0.25-0.48 2,862,687 2.56 $ 0.276 2,862,687 $ 0.276 $ 0.5623-1.00 16,477,022 2.77 $ 0.938 16,477,022 $ 0.938 61,807,992 3.32 $ 0.313 61,807,992 $ 0.313

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the provision for income tax expense with the expected income tax computed by applying the federal statutory income tax rate to income before provision for income taxes was as follows for the years ended December 31, 2017 and 2016: 2017 2016 Income tax computed at federal statutory tax rate -34.0 % -34.0 % Change in valuation allowance 39.8 % 39.8 % State taxes, net of federal benefit -5.8 % -5.8 % Total 0.0 % 0.0 %

Nature of Business and Summar23

Nature of Business and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Debt and equity financing	$ 4,400,000
Unrecognized tax benefits
Research and development expenses	$ 115,159	$ 0
Minimum [Member]
Property plant and equipment, estimated useful lives	5 years
Maximum [Member]
Property plant and equipment, estimated useful lives	7 years
Hanover Portfolio Acquisitions, Inc [Member]
Acquisitions description	On January 22, 2014 Hanover Portfolio Acquisitions, Inc. (the “Company”) received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company’s Certificate of Incorporation to change the name of the Company from “Hanover Portfolio Acquisitions, Inc.” to “Endonovo Therapeutics, Inc.” The name change was affected pursuant to a Certificate of Amendment (the “Certificate of Amendment”), filed with the Secretary of State of Delaware on January 24, 2014.
Common stock, voting rights	Common Stock representing in excess of 50% of the total issued and outstanding voting power

Nature of Business and Summar24

Nature of Business and Summary of Significant Accounting Policies - Schedule of Measured Stock-Based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Expected dividends	0.00%	0.00%
Forfeitures	$ 0
Minimum [Member]
Expected term	2 years	1 year
Exercise price	$ 0.0216	$ 0.0113
Expected volatility	184.00%	176.00%
Risk-free interest rate	1.50%	0.45%
Maximum [Member]
Expected term	5 years	2 years
Exercise price	$ 0.2669	$ 0.81
Expected volatility	217.00%	276.00%
Risk-free interest rate	1.87%	1.06%

Nature of Business and Summar25

Nature of Business and Summary of Significant Accounting Policies - Schedule of Balances of Liabilities Measured at Fair Value (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Derivative liability	$ 5,939,600	$ 1,927,752
Total	5,939,600	1,927,752
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Derivative liability
Total
Significant Other Observable Inputs (Level 2) [Member]
Derivative liability
Total
Significant Unobservable Inputs (Level 3) [Member]
Derivative liability	5,939,600	1,927,752
Total	$ 5,939,600	$ 1,927,752

Nature of Business and Summar26

Nature of Business and Summary of Significant Accounting Policies - Schedule of Changes in the Liabilities with Significant Unobservable Inputs (Details) - Derivative Liability [Member] - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Liabilities with significant unobservable inputs , beginning balance	$ 1,927,752	$ 3,973,542
Increase in Derivative Liability resulting from Issuance of convertible debt	9,185,674	2,525,515
Decrease in Derivative Liability resulting from Settlements by debt extinguishment	(8,156,369)	(1,718,013)
Decrease/Increase in Derivative Liability resulting from Change in estimated fair value	2,982,543	(2,853,292)
Liabilities with significant unobservable inputs, ending balance	$ 5,939,600	$ 1,927,752

Nature of Business and Summar27

Nature of Business and Summary of Significant Accounting Policies - Schedule of Variable Debentures Black-Scholes Valuation Assumptions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Expected dividends	0.00%	0.00%
Forfeitures	$ 0
Minimum [Member]
Expected term	2 years	1 year
Exercise price	$ 0.0216	$ 0.0113
Expected volatility	184.00%	176.00%
Risk-free interest rate	1.50%	0.45%
Maximum [Member]
Expected term	5 years	2 years
Exercise price	$ 0.2669	$ 0.81
Expected volatility	217.00%	276.00%
Risk-free interest rate	1.87%	1.06%
Derivative Liability [Member]
Expected term	1 year
Expected dividends	0.00%
Forfeitures
Derivative Liability [Member] | Minimum [Member]
Exercise price	$ 0.0063
Expected volatility	163.00%
Risk-free interest rate	0.79%
Derivative Liability [Member] | Maximum [Member]
Exercise price	$ 0.385
Expected volatility	201.00%
Risk-free interest rate	1.76%

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 14,761	$ 15,833

Property and Equipment - Summar

Property and Equipment - Summary of Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment, gross	$ 78,232	$ 78,232
Less accumulated depreciation	77,168	62,407
Property, Plant and Equipment, net	1,064	15,825
Autos [Member]
Property, Plant and Equipment, gross	64,458	64,458
Medical Equipment [Member]
Property, Plant and Equipment, gross	5,000	5,000
Other Equipment [Member]
Property, Plant and Equipment, gross	$ 8,774	$ 8,774

Patents (Details Narrative)

Patents (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Acquisition of patents	$ (3,000,000)
Settlement Agreement [Member]
Acquisition of patents	$ 4,500,000	$ 4,500,000
Patents expire period	2,024
Patent amortization description	Patent portfolio is amortized through 2024

Patents - Schedule of Patents L

Patents - Schedule of Patents Less Accumulated Amortization (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 4,500,000
Less accumulated amortization
Total	$ 4,500,000

Patents - Schedule of Estimated

Patents - Schedule of Estimated Future Amortization Expense (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
2,018	$ 646,910
2,019	646,910
2,020	646,910
2,021	646,910
2,022	646,910
Thereafter	1,265,450
Total	$ 4,500,000

Notes Payable and Long Term L33

Notes Payable and Long Term Loan (Details Narrative) - USD ($)	1 Months Ended				12 Months Ended
	Aug. 31, 2015	Oct. 31, 2014	Jul. 31, 2014	Oct. 31, 2013	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2012
Proceeds from issuance of note payable					$ 4,047,000	$ 1,491,778
Note payable outstanding					4,461,160	1,878,107
Number of shares issued in connection with note conversions					4,975,950	1,957,717
Warrant to purchase of common stock							300,000
Note payable related parties					$ 270,000	$ 170,000
Debt effective interest rate					222.00%	89.00%
IPR [Member]
Long-term acquisition payable for costs not paid at closing								$ 155,000
Percentage of proceeds from any private placement or gross profits								25.00%
Two Notes Payable Agreements [Member]
Debt instrument face amount						$ 70,000
Debt instrument, interest rate						10.00%
Note payable outstanding					$ 0	$ 60,000
Debt maturity date						May 31, 2017
Number of shares issued under notes						140,000
Convertible Debentures [Member] | Minimum [Member]
Debt instrument, term					6 months	6 months
Initial principal annual interest rates					6.00%	6.00%
Debt discount rate percentage					25.00%	25.00%
Percentage of issuance note of premium					120.00%	120.00%
Convertible Debentures [Member] | Maximum [Member]
Debt instrument, term					2 years	2 years
Initial principal annual interest rates					10.00%	10.00%
Debt discount rate percentage					53.00%	53.00%
Percentage of issuance note of premium					130.00%	130.00%
Notes Payable [Member]
Note payable outstanding					$ 919,903	$ 1,065,000
Debt discount amount					(2,624,984)	(1,145,849)
Number of shares issued in connection with note conversions					(1,483,285)	(682,690)
Convertible Debentures [Member]
Debt instrument face amount					$ 3,947,000	$ 1,421,778
Debt instrument, interest rate					10.00%	10.00%
Convertible debentures outstanding amount					$ 4,137,070	$ 1,744,416
Debt discount amount					4,087,500	1,723,471
Number of shares issued in connection with note conversions					48,065,178
Convertible Debentures One [Member]
Convertible debentures outstanding amount					4,566,241	1,888,456
Convertible Debentures Two [Member]
Convertible debentures outstanding amount					202,500	66,000
Notes Payable One [Member]
Debt instrument face amount					$ 1,500,000
Debt instrument, interest rate					8.00%
Note payable outstanding					$ 1,500,000
Debt maturity date					Nov. 30, 2018
Notes Payable Two [Member]
Debt instrument face amount					$ 100,000
Debt instrument, interest rate					10.00%
Note payable outstanding					$ 100,000
Debt maturity date					Feb. 28, 2018
Warrant to purchase of common stock					500,000
Warrant to purchase of common stock, value					$ 21,204
Private Placement [Member]
Debt instrument face amount	$ 500,000	$ 500,000	$ 500,000	$ 500,000
Proceeds from issuance of note payable	$ 25,000	$ 25,000	$ 25,000	$ 25,000
Debt instrument, interest rate	10.00%	10.00%	10.00%	10.00%
Debt instrument, term	1 year	1 year	1 year	1 year
Shares issued for conversion of notes payable and accrued interest, shares	100,000	50,000	50,000	125,000
Note payable outstanding					$ 919,903	$ 1,075,500

Notes Payable and Long Term L34

Notes Payable and Long Term Loan - Schedule of Notes Payables (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Repayments of notes payable in cash	$ 120,000	$ 166,500
Less amounts converted to stock	4,975,950	1,957,717
Notes Payable [Member]
Notes payable at beginning of period	3,193,956	2,333,751
Notes payable issued	5,837,070	1,776,895
Default interest added to note payable		62,500
Settlements on note payable	(95,597)	(55,000)
Repayments of notes payable in cash	(96,000)	(241,500)
Less amounts converted to stock	(1,483,285)	(682,690)
Notes payable at end of period	7,356,144	3,193,956
Less debt discount	(2,624,984)	(1,145,849)
Note payable, net	4,731,160	2,048,107
Notes payable issued to related parties	270,000	170,000
Notes payable issued to non-related parties	$ 4,461,160	$ 1,878,107

Notes Payable and Long Term L35

Notes Payable and Long Term Loan - Schedule of Maturity Dates of Notes Payable and Long Term Loan (Details)	Dec. 31, 2017USD ($)
Past due	$ 1,292,403
December 31, 2018	6,063,741
Total	7,356,144
Long-term Debt [Member]
December 31, 2018	4,221
Total	4,221
Current portion	4,221
Non-Related Parties [Member]
Past due	1,122,403
December 31, 2018	5,963,741
Total	7,086,144
Related Parties [Member]
Past due	170,000
December 31, 2018	100,000
Total	$ 270,000

Shareholders' Deficit (Details

Shareholders' Deficit (Details Narrative) - USD ($)	1 Months Ended					12 Months Ended
	Mar. 31, 2016	Aug. 31, 2015	Oct. 31, 2014	Jul. 31, 2014	Oct. 31, 2013	Dec. 31, 2017	Dec. 31, 2016	Feb. 22, 2013
Preferred stock, authorized						1,000,000	1,000,000	1,000,000
Preferred stock, par value						$ 0.001	$ 0.001	$ 0.0001
Preferred stock, outstanding						5,000	1,000	100,000
Preferred stock, shares issued						5,000	1,000
Warrants issued to purchase common stock	300,000
Private placement units issued for conversion of notes payable and accrued interest						$ 308,608
Common stock issued, value						$ 5
Shares issued with note payable							$ 11,080
Shares issued for cash							$ 107,079
Number of common stock shares issued for additional services and fees						7,113,760
Number of common stock issued for additional services and fees						$ 1,411,722
Reserved common shares						147,868,000
Stock options, grants						93,203,369
Stock options value						$ 1,139,403
Maximum stock options exercisable						93,203,369
Weighted average grant date fair value of stock options
Warrants term	2 years
Warrant exercise price	$ 0.81
Value of warrants	$ 40,000
Common stock, shares authorized						500,000,000	500,000,000
Independent Contractors [Member]
Stock options estimated life term						3 years
Stock options, grants						25,272,305
Maximum stock options exercisable						67,931,064
Converted deferred compensation						$ 1,467,311
Stock options exercise price						$ 0.0216
Weighted average grant date fair value of stock options						$ 0.03
Lock-Up Agreement [Member]
Common stock, shares issued						379,294	266,617
Common stock issued, value						$ 25,270	$ 111,661
Shares issued with note payable							$ 70,000
Consulting Agreements [Member]
Common stock, shares issued						3,698,022	2,775,000
Common stock issued, value						$ 204,306	$ 953,250
Private Placement [Member]
Shares issued for conversion of notes payable and accrued interest, shares		100,000	50,000	50,000	125,000
Preferred Stock Designated [Member]
Preferred stock, authorized						5,000,000
Series AA Preferred Stock [Member]
Preferred stock, outstanding						5,000	1,000
Series B Convertible Preferred Stock Designated [Member]
Preferred stock, authorized						50,000
Series B Convertible Preferred Stock [Member]
Preferred stock, outstanding
Preferred stock, shares issued
Series C Secured Redeemable Preferred Stock Designated [Member]
Preferred stock, authorized						8,000
Series C Secured Redeemable Preferred Stock [Member]
Sale of stock for preferred stock						700
Sale of stock, consideration						$ 700,000
Warrant value						$ 101,808
Series C Secured Redeemable Preferred Stock [Member] | Maximum [Member]
Warrants issued to purchase common stock						2,725,269
Series C Secured Redeemable Preferred Stock [Member] | March 21, 2018 [Member]
Preferred stock, par value						$ 0.0001
Shares issued, price per share						1,000
Preferred stock dividend per share						$ 20
Common Stock [Member]
Common stock, shares issued
Shares issued for conversion of notes payable and accrued interest, shares						123,163,542	9,476,582
Common stock issued, value
Shares issued with note payable						$ 95,597	$ 14
Shares issued for cash, shares						250,000	566,327
Shares issued for cash						$ 5,050	$ 57
Stock options value
Common Stock [Member] | Settlement Agreement [Member]
Common stock, shares issued						2,142,387
Common stock issued, value						$ 119,282
Shares issued with note payable						$ 95,597
Shares issued with settlement, shares						6,725,000
Shares issued with settlement, value						$ 235,681
Shares issued for cash, shares						250,000
Shares issued for cash						$ 5,050
Number of shares cancelled, shares						180,274
Number of shares cancelled						$ 10,294
Common Stock [Member] | Private Placement [Member]
Common stock, shares issued						46,437,104	9,194,940
Number of warrants issued for cash						$ 1,290,250	$ 1,128,750
Private placement units issued for conversion of notes payable and accrued interest						$ 113,138	$ 308,608
Shares issued for conversion of notes payable and accrued interest, shares						123,163,542	9,476,582
Accrued interest						$ 4,975,949	$ 1,957,717
Shares issued for cash, shares							566,327
Shares issued for cash							$ 107,079
Stock Options [Member]
Range of exercise prices, lower limit						$ 0.0269
Range of exercise prices. Upper limit						$ 0.054
Stock options value						$ 1,139,403
Stock Options [Member] | Maximum [Member]
Stock options estimated life term						10 years
Stock Options [Member] | Minimum [Member]
Stock options estimated life term						3 years
Warrant [Member]
Warrants issued to purchase common stock							9,194,940
Stock options, grants						46,437,100
Range of exercise prices, lower limit						$ 0.0188
Range of exercise prices. Upper limit						$ 1
Warrants term							5 years
Warrant [Member] | Maximum [Member]
Warrants term						5 years
Warrant exercise price							$ 0.90
Warrant [Member] | Minimum [Member]
Warrants term						3 years
Warrant exercise price							$ 0.0825
Warrant 2 [Member]
Warrants issued to purchase common stock						2,300,000
Warrant value						$ 83,453
Warrants term						2 years
Warrant 2 [Member] | Maximum [Member]
Warrant exercise price						$ 0.25
Warrant 2 [Member] | Minimum [Member]
Warrant exercise price						$ 0.0508
Warrant 3 [Member]
Warrants issued to purchase common stock						1,100,678
Warrant value						$ 71,113
Warrants term						5 years
Warrant 3 [Member] | Maximum [Member]
Warrant exercise price						$ 0.267
Warrant 3 [Member] | Minimum [Member]
Warrant exercise price						$ 0.096
Warrant 4 [Member]
Warrants issued to purchase common stock						2,725,269
Warrants term						2 years
Warrant 4 [Member] | Maximum [Member]
Warrant exercise price						$ 0.058
Warrant 4 [Member] | Minimum [Member]
Warrant exercise price						$ 0.047

Shareholders' Deficit - Schedul

Shareholders' Deficit - Schedule of Preferred Stock (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Feb. 22, 2013
Number of shares authorized	1,000,000	1,000,000	1,000,000
Number of shares outstanding	5,000	1,000	100,000
Par value	$ 0.001	$ 0.001	$ 0.0001
Series AA [Member]
Number of shares authorized	1,000,000
Number of shares outstanding	5,000
Par value	$ 0.0001
Liquidation value
Preferred Stock B [Member]
Number of shares authorized	50,000
Number of shares outstanding
Par value	$ 0.0001
Liquidation value	$ 100
Preferred Stock C [Member]
Number of shares authorized	8,000
Number of shares outstanding	700
Par value	$ 0.0001
Liquidation value	$ 1,000
Undesignated [Member]
Number of shares authorized	3,942,000
Number of shares outstanding
Par value
Liquidation value

Shareholders' Deficit - Sched38

Shareholders' Deficit - Schedule of Stock Options Outstanding (Details)	12 Months Ended
	Dec. 31, 2017USD ($)$ / sharesshares
Equity [Abstract]
Stock option outstanding, beginning balance | shares
Stock option outstanding, granted | shares	93,203,369
Stock option outstanding, cancelled | shares
Stock option outstanding, exercised | shares
Stock option outstanding, ending balance | shares	93,203,369
Stock option outstanding, exercisable | shares	93,203,369
Weighted average exercise price, beginning balance | $ / shares
Weighted average exercise price, granted | $ / shares	0.029
Weighted average exercise price, cancelled | $ / shares
Weighted average exercise price, exercised | $ / shares
Weighted average exercise price, ending balance | $ / shares	0.029
Weighted average exercise price, exercisable | $ / shares	$ 0.029
Weighted average remaining contractual term (years), outstanding	3 years 11 months 15 days
Weighted average remaining contractual term (years), exercisable	3 years 11 months 15 days
Aggregated intrinsic value, outstanding | $	$ 2,721,538
Aggregated intrinsic value, exercisable | $	$ 2,721,538

Shareholders' Deficit - Sched39

Shareholders' Deficit - Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range (Details) - Stock Options [Member]	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Range of exercise prices	$ 0.054
Number of Outstanding outstanding | shares	93,203,369
Weighted average remaining contractual life	3 years 11 months 15 days
Weighted average exercise price	$ 0.029
Number of exercisable | shares	93,203,369
Weighted average exercise price exercisable	$ 0.029
Price Range 1 [Member]
Range of exercise prices	$ 0.0540
Number of Outstanding outstanding | shares	19,250,000
Weighted average remaining contractual life	9 years 3 months 15 days
Weighted average exercise price	$ 0.0540
Number of exercisable | shares	19,250,000
Weighted average exercise price exercisable	$ 0.0540
Price Range 2 [Member]
Range of exercise prices	$ 0.0269
Number of Outstanding outstanding | shares	6,022,305
Weighted average remaining contractual life	2 years 8 months 19 days
Weighted average exercise price	$ 0.0269
Number of exercisable | shares	6,022,305
Weighted average exercise price exercisable	$ 0.0269
Price Range 3 [Member]
Range of exercise prices	$ 0.0216
Number of Outstanding outstanding | shares	67,931,064
Weighted average remaining contractual life	2 years 6 months 18 days
Weighted average exercise price	$ 0.0216
Number of exercisable | shares	67,931,064
Weighted average exercise price exercisable	$ 0.0216

Shareholders' Deficit - Sched40

Shareholders' Deficit - Schedule of Warrants Outstanding (Details) - Warrant [Member]	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Shares Outstanding, Beginning Balance | shares	9,494,940
Shares, Granted | shares	52,563,052
Shares outstanding, Cancelled | shares
Shares, Exercised | shares	(250,000)
Shares Outstanding, Ending Balance | shares	61,807,992
Shares Exercisable, Ending Balance | shares	61,807,992
Weighted-Average Exercise Price, Outstanding Beginning Balance | $ / shares	$ 0.33
Weighted-Average Exercise Price, Granted | $ / shares	0.31
Weighted average exercise price, Cancelled | $ / shares
Weighted-Average Exercise Price, Exercised | $ / shares	0.02
Weighted-Average Exercise Price, Outstanding Ending Balance | $ / shares	0.31
Weighted-Average Exercise Price, Exercisable Ending Balance | $ / shares	$ 0.31

Shareholders' Deficit - Sched41

Shareholders' Deficit - Schedule of Warrants Exercise Price Range (Details) - Warrant [Member]	12 Months Ended
	Dec. 31, 2017$ / sharesshares
Range of exercise prices, lower limit	$ 0.0188
Range of exercise prices. upper limit	$ 1
Number of warrants outstanding | shares	61,807,992
Weighted average remaining contractual life	3 years 3 months 26 days
Weighted average exercise price	$ 0.313
Number of warrants exercisable | shares	61,807,992
Weighted average exercise price exercisable	$ 0.313
Price Range 1 [Member]
Range of exercise prices, lower limit	0.0165
Range of exercise prices. upper limit	$ 0.0469
Number of warrants outstanding | shares	15,019,850
Weighted average remaining contractual life	3 years 5 months 9 days
Weighted average exercise price	$ 0.033
Number of warrants exercisable | shares	15,019,850
Weighted average exercise price exercisable	$ 0.033
Price Range 2 [Member]
Range of exercise prices, lower limit	0.0508
Range of exercise prices. upper limit	$ 0.10
Number of warrants outstanding | shares	21,438,396
Weighted average remaining contractual life	3 years 6 months 21 days
Weighted average exercise price	$ 0.075
Number of warrants exercisable | shares	21,438,396
Weighted average exercise price exercisable	$ 0.075
Price Range 3 [Member]
Range of exercise prices, lower limit	0.108
Range of exercise prices. upper limit	$ 0.239
Number of warrants outstanding | shares	6,010,037
Weighted average remaining contractual life	3 years 7 months 6 days
Weighted average exercise price	$ 0.161
Number of warrants exercisable | shares	6,010,037
Weighted average exercise price exercisable	$ 0.161
Price Range 4 [Member]
Range of exercise prices, lower limit	0.25
Range of exercise prices. upper limit	$ 0.48
Number of warrants outstanding | shares	2,862,687
Weighted average remaining contractual life	2 years 6 months 21 days
Weighted average exercise price	$ 0.276
Number of warrants exercisable | shares	2,862,687
Weighted average exercise price exercisable	$ 0.276
Price Range 5 [Member]
Range of exercise prices, lower limit	0.5623
Range of exercise prices. upper limit	$ 1
Number of warrants outstanding | shares	16,477,022
Weighted average remaining contractual life	2 years 9 months 7 days
Weighted average exercise price	$ 0.938
Number of warrants exercisable | shares	16,477,022
Weighted average exercise price exercisable	$ 0.938

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accrual of deferred compensation		$ 720,000
Cash repayment		533,103
Notes payable - related parties	$ 270,000	170,000
Notes Payable	21,983	20,284
Executives [Member]
Deferred compensation	922,395	1,861,327
Accrual of deferred compensation	894,394	894,394
Stock options or warrants value	1,173,297	1,173,297
Due to officer	20,323	5,823
Individuals [Member]
Converted deferred compensation	660,000
Executive Officers [Member]
Related party advances	26,000	12,618
Repayment of related party debt	11,500	10,300
Repayment of accrued interest	22,100	0
Executive [Member]
Notes payable - related parties	100,000	50,000
Repayment of debt	75,000
One Executive [Member]
Notes payable - related parties	$ 270,000	$ 170,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Federal net operating loss carry forwards	$ 14,000,000
Federal net operating loss carry forwards expire date	begin to expire in 2029
Deferred tax, valuation allowance percentage	100.00%
Interest and penalties	$ 0	$ 0

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income tax computed at federal statutory tax rate	(34.00%)	(34.00%)
Change in valuation allowance	39.80%	39.80%
State taxes, net of federal benefit	(5.80%)	(5.80%)
Total	0.00%	0.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	1 Months Ended				12 Months Ended
	Aug. 31, 2015shares	Oct. 31, 2014shares	Jul. 31, 2014shares	Oct. 31, 2013shares	Dec. 31, 2017USD ($)Integershares	Dec. 31, 2016USD ($)shares	Mar. 31, 2016shares	Feb. 22, 2013shares
Warrants issued to purchase common stock							300,000
Issuance of shares of common stock, amount | $					$ 5
Common stock, shares outstanding					316,951,712	134,336,637
Preferred stock, outstanding					5,000	1,000		100,000
Preferred Stock B [Member]
Preferred stock, outstanding
Preferred Stock C [Member]
Preferred stock, outstanding					700
Lock-Up Agreement [Member]
Issuance of shares of common stock, amount | $					$ 25,270	$ 111,661
Private Placement [Member]
Number of shares issued to note conversion	100,000	50,000	50,000	125,000
Subsequent Event [Member]
Issuance of restricted common stock, shares					19,327,397
Convertible debt | $					$ 477,491
Accrued interest | $					$ 36,039
Common stock, shares outstanding					341,345,596
Subsequent Event [Member] | Three Notes [Member]
Cash received | $					$ 625,000
Warrant value | $					$ 705,370
Number of shares issued to note conversion					3,387,534
Subsequent Event [Member] | One Notes [Member] | Maximum [Member]
Warrants issued to purchase common stock					2,000,000
Subsequent Event [Member] | Preferred Stock B [Member]
Warrants issued to purchase common stock					5,076,111
Issuance of shares of common stock, amount | $					$ 1,350
Preferred stock, outstanding					1,350
Subsequent Event [Member] | Preferred Stock C [Member]
Warrants issued to purchase common stock					5,076,111
Issuance of shares of common stock, amount | $					$ 60
Preferred stock, outstanding					760
Subsequent Event [Member] | Private Placement [Member]
Issuance of restricted common stock, shares					1,561,950
Warrants issued to purchase common stock					1,561,950
Issuance of shares of common stock, amount | $					$ 60,000
Number of investors | Integer					3
Subsequent Event [Member] | Restricted Common Stock [Member]
Cash received | $					$ 195,000
Subsequent Event [Member] | Restricted Common Stock [Member] | Lock-Up Agreement [Member]
Issuance of restricted common stock, shares					17,003
Subsequent Event [Member] | Restricted Common Stock [Member] | Independent Contractors [Member]
Issuance of restricted common stock, shares					100,000
Warrants issued to purchase common stock					6,200,000